Natera
在场
Natera 的所有者是 LifeLabs.
LifeLabs 在 3 个国家有直接业务。
LifeLabs 拥有 4家子公司，其中包括 Centogene、Hemostasis Reference Laboratory 和 NanoString Technologies。
他们在：
高管
查看带有其 34 名主要高管的组织结构图
Natera 搜索最多的简介
高管在Natera变化
- Solomon Moshkevich 曾任 General Manager, Oncology, 现升职为 President of Clinical Diagnostics (新闻发布的2023九月19号).
- John Fesko 曾任 Chief Business Officer, 现升职为 President and Chief Business Officer (新闻发布的2023九月19号).
- Alexey Aleshin 曾任 General Manager, Early Cancer Detection, 现升职为 General Manager of Oncology and Early Cancer Detection (新闻发布的2023九月19号).
创建提醒
跟踪 Natera 的高管变动
生物技术
LifeLabs 拥有 2,277 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Histogen has filed for bankruptcy protection (公布2024四月19号).
- Bruker has announced the acquisition of NanoString Technologies (公布2024四月18号).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (公布2024四月16号).
生物技术 行业的其他推荐联系人
消息
Natera 的最新新闻稿
- Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents
- Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
- Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
- Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
- Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test
- Natera Reports First Quarter 2023 Financial Results
- Natera Announces New Publication from I-SPY2 Trial Reinforcing Clinical Utility of Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
- Natera Announces First Quarter 2023 Earnings Conference Call
- Natera Announces New Signatera™ MRD Data at 2023 AACR Annual Meeting
- New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma
- View more press releases Close
通过电子邮件
